Wolfgang Brück

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5689075/publications.pdf Version: 2024-02-01



WOLFCANC RDÃ1/4CK

#	Article	IF	CITATIONS
1	Iron Heterogeneity in Early Active Multiple Sclerosis Lesions. Annals of Neurology, 2021, 89, 498-510.	5.3	22
2	Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes. Neurology, 2021, 97, e1906-e1913.	1.1	18
3	B cells reappear less mature and more activated after their anti-CD20–mediated depletion in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25690-25699.	7.1	44
4	Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	13
5	B cell depletion can be effective in multiple sclerosis but failed in a patient with advanced childhood cerebral X-linked adrenoleukodystrophy. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641986813.	3.5	1
6	A case of CLIPPERS syndrome responsive to tocilizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e545.	6.0	9
7	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	12.8	87
8	Therapy of highly active pediatric multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 72-80.	3.0	60
9	Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurology, 2018, 75, 428.	9.0	54
10	CLIPPERS with longitudinally extensive transverse myelitis: Role of T versus B cells. Journal of the Neurological Sciences, 2018, 385, 96-98.	0.6	7
11	Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade l–IV astrocytic brain tumors. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1227-1237.	2.5	15
12	Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9773-9778.	7.1	82
13	Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology, 2018, 91, e359-e363.	1.1	20
14	An updated histological classification system for multiple sclerosis lesions. Acta Neuropathologica, 2017, 133, 13-24.	7.7	436
15	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. Molecular Therapy, 2017, 25, 2620-2634.	8.2	199
16	The Early Adaptive Immune Response in the Pathophysiological Process of Pneumococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 150-158.	4.0	9
17	Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. Acta Neuropathologica, 2016, 132, 43-58.	7.7	75
18	Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e257.	6.0	178

Wolfgang Brück

#	Article	IF	CITATIONS
19	Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e233.	6.0	15
20	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e204.	6.0	53
21	Glial Cells Express Nuclear Nrf2 After Fumarate Treatment for Multiple Sclerosis and Psoriasis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e99.	6.0	17
22	Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Annals of Neurology, 2015, 78, 710-721.	5.3	485
23	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. International Journal of Molecular Sciences, 2015, 16, 16880-16896.	4.1	4
24	Complement-associated neuronal loss in a patient with CASPR2 antibody–associated encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e75.	6.0	50
25	Natalizumab analogon therapy is effective in a <scp>B</scp> cellâ€dependent multiple sclerosis model. Neuropathology and Applied Neurobiology, 2015, 41, 814-831.	3.2	6
26	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.1	49
27	Pathologic heterogeneity persists in early active multiple sclerosis lesions. Annals of Neurology, 2014, 75, 728-738.	5.3	110
28	Accumulation and therapeutic modulation of 6-sulfo LacNAc ⁺ dendritic cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e33.	6.0	28
29	Anti-inflammatory Disease Therapies. Toxicologic Pathology, 2012, 40, 122-125.	1.8	1
30	Neuromyelitis optica lesions may inform multiple sclerosis heterogeneity debate. Annals of Neurology, 2012, 72, 385-394.	5.3	67
31	Inflammatory Cortical Demyelination in Early Multiple Sclerosis. New England Journal of Medicine, 2011, 365, 2188-2197.	27.0	922
32	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet, The, 2005, 366, 579-582.	13.7	411
33	Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Annals of Neurology, 2000, 47, 707-717.	5.3	2,892
34	Monocyte/macrophage differentiation in early multiple sclerosis lesions. Annals of Neurology, 1995, 38, 788-796.	5.3	427